Skip to main content
Rural Health Information Hub

HHS: Medications for the Treatment of Opioid Use Disorder

Federal Register
Feb 2, 2024
Notice of final rule from the U.S. Department of Health and Human Services (HHS), Substance Abuse and Mental Health Services Administration (SAMHSA) modifying and updating certain regulatory provisions related to opioid treatment program (OTP) accreditation, certification, and standards for the treatment of opioid use disorder (OUD) with medications for opioid use disorder (MOUD). These changes include making flexibilities established during the COVID-19 Public Health Emergency (PHE) permanent and expanding access to care and evidence-based treatment for OUD. This rule also removes all language and rules relating to the Drug Addiction and Treatment Act (DATA) Waiver from the regulations pursuant to the Consolidated Appropriations Act, 2023. This rule is effective April 2, 2024, and the compliance date is April 2, 2026.
Tagged as
Access · Accreditation · Healthcare business and finance · Illicit drug use · Legislation and regulations · Pharmacy and prescription drugs · Prescription drug misuse · Substance use and misuse